VERTEX PHARMACEUTICALS INC / MA
Close on Oct 19, 2026
- Market cap
- $128.10B
- P/E (TTM)
- 29.2
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | During market hours | $3.33B | $4.31 | $4.73 |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | During market hours | $2.99B | $4.02 | $4.47 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | During market hours | $3.19B | $4.65 | $5.03 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | During market hours | $2.96B | $3.99 | $4.52 |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | During market hours | $2.77B | $2.49 | $4.06 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 10, 2025 | During market hours | $2.91B | $3.50 | $3.98 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 4, 2024 | During market hours | $2.77B | $4.01 | $4.38 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 5, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 3, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Combined GAAP R&D, AIPR&D and SG&A expensesGAAP | full year 2026 | $6.30B to $6.45B | Maintained |
| Combined non-GAAP R&D, AIPR&D and SG&A expensesnon-GAAP | full year 2026 | $5.65B to $5.75B | Maintained |
| Non-GAAP effective tax ratenon-GAAP | FY 2026 | 19.5% to 20.5% | Maintained |
| Total revenue | full year 2026 | $13.10B to $13.20B | Raised |
| non-CF products | 2026 | $500.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Vertex Pharmaceuticals Inc / Ma filed with the SEC
Vertex Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
PHARMACEUTICALS July 6, 2026 Presentation intended for the investment community ©2026 Vertex Pharmaceuticals Incorporated ©2026 Vertex Pharmaceuticals Incorporated
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vertex Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports Second Quarter 2025 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Vertex Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Vertex Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative
Other events · EX-99.1 to Form 8-K
Vertex Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Reconciliation of Reported to Revised GAAP to Non-GAAP Net Income
Results of operations · EX-99.2 to Form 8-K